/PRNewswire/ Pharming Group N.V. ("Pharming" or the "Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that it has received a positive decision.
Pharming Group N V : Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in EuropeAn agreed PIP is the regulatory pathway to market authorization for leniolisib as a treatment of activated phosphoinositide 3-kinase delta syndrome in childrenLeiden, The Netherlands, 06 January, 2022: Pharming Gro.